Nienke P.M. Wassenaar1, Esther N. Pijnappel2, Remy Klaassen2, Femke Struik1, Jaap Stoker1, Jurgen H. Runge1, Hanneke W.M. van Laarhoven2, Johanna W. Wilmink2, Aart J. Nederveen1, and Oliver J. Gurney-Champion1
1Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 2Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
1Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 2Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
The
diffusion in PDAC increased after treatment with the combination therapy LDE225
and gemcitabine+nab-paclitaxel. Increase in IVIM-derived perfusion may be used
as predictive biomarker for treatment response with an AUC of 0.835.
Figure 1: MRI scans of 1 patient
at baseline and post chemotherapy. The primary tumour is manually delineated
and indicated in red. The diffusion increased with 23%, perfusion fraction and
pseudodiffusion decreased with 32% and 58% respectively.
Figure 3: Plot of IVIM parameters at
baseline and post chemotherapy. Only D shows a significant increase (p<0.001).
The diffusion of the tumour increased after the chemotherapy.
